# Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

> **NCT02073279** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 95 (actual)

## Conditions studied

- Neuromyelitis Optica (NMO)
- NMO Spectrum Disorder (NMOSD)

## Interventions

- **DRUG:** Satralizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02073279
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-05
- **Primary completion:** 2018-10-12
- **Final completion:** 2022-01-31
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2023-03-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02073279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02073279, "Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT02073279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*